• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.

View in: PubMed

subject areas
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Aniline Compounds
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Resistance, Neoplasm
  • Female
  • fms-Like Tyrosine Kinase 3
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute
  • Liver
  • Male
  • Middle Aged
  • Mutation
  • Pyrazines
  • Recurrence
  • Remission Induction
  • Salvage Therapy
  • Survival Analysis

authors with profiles
  • Robert K. Stuart